Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

INSULIN GLARGINE & LIXISENATIDE

All injection strengths: general benefit

Soliqua · DIN 02478293 · 100U/mL & 33mcg/mL · injection solution-pre-filled pen 5x3mL Pk

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Soliqua · DIN 02478293 Manufacturer: Sanofi-Aventis Canada Inc.; listing date 2019-12-20 Health Canada: Marketed since 2018-09-12 · brand SOLIQUA · ATC A10AE54 INSULIN GLARGINE AND LIXISENATIDE, A10AE54 INSULIN GLARGINE AND LIXISENATIDE · form Solution · route Subcutaneous · ingredients LIXISENATIDE 33 MCG/ML, INSULIN GLARGINE 100 UNIT/ML · company Sanofi-aventis canada inc · schedule Prescription, Schedule d
Check this DIN again · Health Canada product record

Soliqua: Formulary list price $206.6000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $206.6000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96906 · Verify on the e-Formulary ↗ (DIN 02478293)

Source record
DIN 02478293: Soliqua Raw flags: insOH=Y, sec3=Y Item: 682006005; group id 758; item number 1863; lccId None; manufacturer id SAC Source form: Inj Sol-Pref Pen 5x3mL Pk; strength: 100U/mL & 33mcg/mL Recorded listing: General benefit; diabetes medication flag Source prices (unrounded): $206.6000; ministry $206.6000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02478293 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96906 Therapeutic Notes (formulary) As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus inadequately controlled on basal insulin (less than 60 units daily) in combination with metformin.
Shortage status: resolved shortage (ended 2022-08-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02478293
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (68:20:06 Incretin Mimetics) and how they are covered

Matched class: 68:20:06 Incretin Mimetics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. No displayed product is listed as a general benefit in this extract. Check its listing requirements below. 68:20:06 Incretin Mimetics

SEMAGLUTIDE

· 13 products · Limited Use, codes 667 (2), Limited Use, codes 666 (2), Limited Use, codes 665 (3), Limited Use, codes 738 (1), Limited Use, codes 662 (1), Limited Use, codes 739 (1), Limited Use, codes 663 (1), Limited Use, codes 740 (1), Limited Use, codes 664 (1) · strengths: 0.68mg/mL, 1.34mg/mL, 1.5mg, 3mg, 4mg, 7mg, 9mg, 14mg · Inj Sol - Pref Pen 3mL Pk, Inj Sol-Pref Pen 1.5mL Pk, Inj Sol-Pref Pen 3mL Pk, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:20:06
Full class listing Related classes: 68:20:02 Oral Anti-Diabetic Agents, 68:20:10 Insulins (Rapid Acting), 68:20:12 Insulins (Intermediate Acting), 68:20:14 Insulins (Long Acting), 68:20:16 Insulins (Pre-Mixed) Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications SOLIQUA, a fixed ratio combination of insulin glargine and lixisenatide, once daily injection, is indicated in combination with metformin as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus inadequately controlled on: • basal insulin (less than 60 units daily) alone or in combination with metformin • a glucagon-like peptide-1 receptor agonist (GLP-1RA) in combination with metformin Use alternative antidiabetic products if patients require basal insulin below 15 units or over 60 units. See 4 Dosage and Administration Therapy with basal insulin or a GLP-1RA should be discontinued prior to initiation of SOLIQUA, since SOLIQUA contains both basal insulin and a GLP-1RA (lixisenatide). Limitations of Use • SOLIQUA has not been studied with short acting insulin. • SOLIQUA should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. • SOLIQUA is not recommended for use in combination with any other product containing lixisenatide or another GLP-1RA. • SOLIQUA has not been studied in patients with a history of pancreatitis. Co… https://pdf.hres.ca/dpd_pm/00082751.PDF PM date: 2025-12-11 Source product: SOLIQUA; DIN 02478293; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.